Pharmacokinetics and safety of fidaxomicin in patients with inflammatory bowel disease and Clostridium difficile infection: An open-label Phase IIIb/IV study (PROFILE)
(2018)
Journal Article
Mahida, Y., Stallmach, A., Marteau, P., Rydzewska, G., Ivashkin, V., Gargalianos-Kakolyris, P., …Högenauer, C. (2018). Pharmacokinetics and safety of fidaxomicin in patients with inflammatory bowel disease and Clostridium difficile infection: An open-label Phase IIIb/IV study (PROFILE). Journal of Antimicrobial Chemotherapy, 73(12), 3430-3441. https://doi.org/10.1093/jac/dky368
©The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. Objectives Inflammatory bowel disease (IBD) poses an increased risk for Clostridium difficile infection (CDI). Fidaxomicin has... Read More about Pharmacokinetics and safety of fidaxomicin in patients with inflammatory bowel disease and Clostridium difficile infection: An open-label Phase IIIb/IV study (PROFILE).